Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Lenacapavir/islatravir combo carries mechanistic rationale Mixed oral/subQ regimens don’t provide additional convenience ...

A few days later, confidence in the drug was dented again when Gilead Sciences called a halt to a mid-stage trial of islatravir given alongside its HIV capsid inhibitor lenacapavir, which is ...

namely ViiV Healthcare with cabotegravir and Merck & Co’s islatravir (MK-8591). The 36-patient CAPELLA trial tested lenacapavir in highly treatment-experienced HIV patients who had developed ...

Lenacapavir showed a 96% reduction in HIV infections, outperforming daily F/TDF in the PURPOSE 2 trial. The trial included a diverse global population, with 67% non-White participants, enhancing ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor ...

7 October 2024 (Lima, Peru) – New data from the PURPOSE 2 study of twice-yearly lenacapavir for HIV prevention are among the scientific highlights at HIVR4P 2024, the 5th HIV Research for Prevention ...

Lenacapavir reduced HIV infections by 96% compared to background HIV incidence. At interim analysis, the independent Data Monitoring Committee confirmed that the PURPOSE 2 trial met its key ...

Gilead has unveiled positive topline results from an interim analysis of its Phase III PURPOSE 2 trial showing that its twice-yearly HIV drug lenacapavir outperformed once-daily Truvada ...